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AIMS—We compared cystatin C in youth with versus without diabetes and determined factors 
associated with cystatin C in youth with type 1 diabetes (T1D) and type 2 diabetes (T2D).
METHODS—Youth (ages 12–19 years) without diabetes (N=544) were ascertained from the 
NHANES Study 2000- 2002 and those with T1D (N=977) and T2D (N=168) from the SEARCH 
for Diabetes in Youth Study. Adjusted means of cystatin C concentrations were compared amongst 
the 3 groups. Next, we performed multivariable analyses within the T1D and T2D SEARCH 
samples to determine the association between cystatin C and race, sex, age, diabetes duration, 
HbA1c, fasting glucose, and BMI.
RESULTS—Adjusted cystatin C concentrations were statistically higher in NHANES (0.85mg/L) 
than in either the T1D (0.75mg/L) or T2D (0.70mg/L) SEARCH groups (p<0.0001). Fasting 
glucose was inversely related to cystatin C only in T1D (p<0.001) and BMI positively associated 
only in T2D (p<0.01) while HbA1c was inversely associated in both groups.
CONCLUSIONS—Cystatin C concentrations are statistically higher in youth without diabetes 
compared to T1D or T2D, however the clinical relevance of this difference is quite small, 
especially in T1D. In youth with diabetes, cystatin C varies with BMI and acute and chronic 
glycemic control, however their effects may be different according to diabetes type.
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SECTION 1.0 INTRODUCTION
Diabetes is the leading cause of chronic kidney disease (CKD) in the U.S. and carries 
significant morbidity and mortality [1]. As glomerular filtration rate (GFR) deteriorates, the 
risk for end-stage renal disease, cardiovascular events and death increases substantially [2]. 
Recent data show that the prevalence of type 1 and type 2 diabetes in youth is increasing [3]. 
Diabetes onset in youth increases the lifetime exposure to the diabetic milieu resulting in a 
greater risk for developing CKD. Several reports have suggested that type 2 diabetes (T2D) 
in youth takes a particularly aggressive course, with renal complications beginning earlier 
than in type 1 diabetes (T1D) [4, 5]. These issues underscore the importance of 
understanding the natural history of markers of early chronic kidney disease in youth with 
diabetes.
Serum cystatin C has gained prominence as an endogenous marker of GFR [6]. Cystatin C is 
a low molecular weight cysteine protease inhibitor, produced by all nucleated cells, freely 
filtered by the glomerulus and catabolized in the renal tubular cells without reabsorption, 
and its reciprocal is highly correlated with the GFR [7]. The American Diabetes Association 
recommends annual GFR measurement in adolescents with diabetes [8]. Numerous studies 
in adults [9–12] and children [13–15] have demonstrated that serum cystatin C improves 
estimates of GFR than serum creatinine-based methods alone. Analyses by diabetes status 
have confirmed that cystatin C improves the accuracy and precision of GFR estimation even 
in this distinct population [12, 16]
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Factors other than GFR can impact cystatin C concentrations, and depending on the 
population, these factors need to be considered when interpreting cystatin C-based estimated 
GFR (eGFR). In adults, cystatin C concentration increases with age, inflammation [17] and 
high-dose glucocorticoid therapy [18] while lower concentrations are seen in 
hypothyroidism [19]. Data reflecting non-GFR factors that influence cystatin C are limited, 
especially in youth. The Third National Health and Nutrition Examination Survey 
(NHANES) III found that cystatin C concentrations were higher in males and decreased with 
advancing age in children and adolescents [20]. In a study of youth with T1D, cystatin C 
was shown to be lower with advancing age, female sex, increased body mass index (BMI), 
increased glycated hemoglobin (HbA1c), and increased C-reactive protein [21] . This is the 
only report of comparison of cystatin C concentrations in youth with T1D versus youth 
without diabetes. No difference was found but this has not been confirmed [21]. Factors 
influencing cystatin C have not been previously reported in youth with T2D. As an 
important marker of kidney disease, insight to these factors is crucial to better understand 
the early natural history of cystatin C-based eGFR in youth with diabetes. Our objectives 
were twofold: 1) to compare the distribution of cystatin C among youth without diabetes 
versus T1D and T2D; and 2) to determine the factors associated with cystatin C in youth 
with T1D and T2D.
SECTION 2.0 SUBJECTS, MATERIALS AND METHODS
2.1: Population without self-reported diabetes: NHANES
Continuous NHANES is a cross-sectional epidemiologic study of a nationally representative 
sample of the non-institutionalized civilian U.S. population conducted in two-year cycles 
starting in 1999. This analysis includes NHANES 2001–2002 participants aged 12–19 years, 
without self-reported diabetes and with measured serum cystatin C (n = 544). NHANES 
instruments, methods and measures have been described previously (http://www.cdc.gov/
nchs/about/major/nhanes/datalink.htm). Weight and height were recorded and BMI was 
calculated. Blood pressure (BP) was measured in the seated position after a 5-minute rest 
period. HbA1c was measured by boronate-affinity high-performance liquid chromatography 
(Primus Corp, Kansas City, MO). Cystatin C was measured in a random 25% sample of 
NHANES participants aged 12–59 years (http://www.cdc.gov/nchs/nhanes/
nhanes2001-2002/SSCYST_B.htm).
Cystatin C was measured in 2006 using a Siemens automated particle-enhanced 
nephelometric assay on serum samples collected from NHANES participants in 2001–2002, 
stored at −70°C. In 2011, it was reported that the calibration of the assay for cystatin C had 
drifted during the 2006–2010 period such that there was a 15% decrease in cystatin C values 
reported after 2008 [22] . To correct for this drift in the NHANES data, equations were 
developed to standardize the cystatin C results by making them traceable to the International 
Federation of Clinical Chemistry (IFCC) Standard ERM DA 471 [23]. The equation is as 
follows: Adjusted cystatin C= [(raw cystatin C)−0.12]×1.12. Since the cystatin C assay was 
run in 2006, we followed the recommended standardization to make it comparable to the 
IFCC standard.
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2.2 Population with diagnosed diabetes: SEARCH
SEARCH is a multi-center, longitudinal study of youth with type 1 and type 2 diabetes, 
diagnosed prior to the age of 20 years. A detailed description of SEARCH methodology is 
published elsewhere [24]. Briefly, incident cases of diabetes from 2002–2010 were identified 
through a reporting network of clinics, healthcare providers, school nurses and diabetes 
educators. Study sites were located in geographically defined populations in Ohio, 
Washington, South Carolina and Colorado and among health plan enrollees in Hawaii 
(Hawaii Medical Service Association, Med-Quest, Kaiser Permanente Hawaii) and in 
southern California (Kaiser Permanente). Patients were invited for an in-person visit at 
baseline and follow up visits at 12, 24 and 60 months. In this analysis we included 
participants with an in-person visit and with measured serum cystatin C between July 2002 
and September 2010 (n=1145). If participants had more than one visit during this time 
interval, we used the earliest visit. Diabetes “type” was defined by the healthcare provider’s 
diagnosis. We excluded 9 participants with “other” forms of diabetes that were not classified 
as T1D or T2D (4 with monogenic diabetes, 1 hybrid, 4 unknown type).
2.3 Measurements
During the in-person visit, height and weight were measured and used to calculate BMI (kg/
m2), which was then converted to z-scores using the standard Centers for Disease Control 
and Prevention (CDC) approach [25]. BP was obtained in the seated position after at least a 
5-minute rest period. BP Z-scores were calculated by adjusting for age, sex and height based 
on CDC growth references for 2000 [25]. Fasting blood samples were drawn at a time of 
metabolic stability when the participants were free of diabetic ketoacidosis or infection, for 
determination of glucose, HbA1c and cystatin C. Urinary creatinine was measured by the 
Jaffe method using Roche reagent on the Roche Modular P autoanalyzer on random spot 
urine samples. Urine albumin was measured in the same samples immunochemically using 
Siemens reagent on a Siemens BNII nephelometer and the urine albumin/creatinine ratio 
was calculated. Samples were processed locally and shipped within 24 hours to the central 
laboratory (Northwest Lipid Metabolism and Diabetes Research Laboratories). HbA1c was 
measured by non-porous ion-exchange high-performance liquid chromatography on a 
TOSOH G8 dedicated analyzer (TOSOH Biosciences Inc., South San Francisco, CA). 
Cystatin C was measured using Siemens reagent on a BNII nephelometer (Siemens 
Healthcare Diagnostics). SEARCH noted the same assay drift as previously described [22], 
however, there appeared to be two somewhat distinct drift periods that diverged in mid-2008. 
Using Deming regression models [26], two independent calibration equations were 
provided, making them traceable to the IFCC Standard (see Supplemental Data 1 for further 
details).
For assays performed in years prior to 5/1/2008 the equation was:
For assays performed between 5/1/2008–4/7/2014 the equation was:
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All summary measures from the NHANES data are reported after incorporating the specific 
sample weights that account for the probability of having a cystatin C measurement and the 
complex survey design. For continuous measures, two sample t-tests were used to compare 
SEARCH T1D and T2D with NHANES. Chi-square tests were used for categorical 
measures to compare SEARCH T1D and T2D with NHANES. Cystatin C measures were 
evaluated overall, by diabetes type, and subcategorized by age (12–14, 15–19), sex, and 
race/ethnicity. The distribution of cystatin C was confirmed to approximate a normal 
distribution. Analysis of covariance (ANCOVA) models were used to estimate the mean 
cystatin C concentration after adjusting for age, sex, and race/ethnicity in both NHANES 
and SEARCH studies. These adjusted means were then compared using an inverse-variance 
weighted test to evaluate differences between the studies and by diabetes type.
To investigate the effect of clinical characteristics on cystatin C, by diabetes type within 
SEARCH, several approaches were used. Specifically, analyses were performed separately 
for T1D and T2D participants. For each group, three model selection approaches were used 
considering the variables: sex, race (black vs. other), age at diagnosis, duration of diabetes, 
blood glucose, HbA1c, and BMI Z-score. These approaches included a stepwise selection 
method, a backwards selection method and a LASSO (least absolute shrinkage and selection 
operator) approach [27]. For the two selection approaches, variables were selected (or 
retained) using a p-value of 0.1 or less at each iteration to create the final models, and for the 
LASSO approach the Schwarz Bayesian information criteria [28] with 30 selection steps 
was used to identify the best model. Each of the “best” models were compared among the 
three methods and if they were in agreement then the model that was produced using a 
selection method would be used. If there were differences among the “best” models, then 
additional diagnostics would be used to determine the preferred final model, specifically, the 
correlation among potential predictors was examined to determine if there was evidence of 
collinearity among any predictors in the final model and if so then a model removing the 
least significant variable that had a collinear relationship with other variables was removed. 
The resulting adjusted means for T1D and T2D were compared using an inverse-variance 
weighted test. All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, 
NC).
Section 3.0 RESULTS
3.1 Distribution of cystatin C in youth with and without diabetes
A total of 1145 cystatin C measures from SEARCH (977 T1D and 168 T2D) collected 
between July 2002 and September 2010 in participants aged 12–19 years were compared to 
544 measures from NHANES participants aged 12–19 years without diagnosed diabetes. 
Demographic and clinical characteristics of NHANES versus SEARCH participants, 
stratified by diabetes type, are outlined in Table 1. There are clear differences amongst the 
three groups with respect to almost all characteristics including age, sex and race/ethnicity.
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The distribution of raw cystatin C is depicted in Figure 1a with mean cystatin C being higher 
in the NHANES group compared with SEARCH. Figure 1b depicts the distribution of 
cystatin C values in NHANES and SEARCH (overall and by diabetes type), subcategorized 
by age, sex and race/ethnicity. Serum cystatin C was higher in NHANES compared with 
SEARCH across all strata of age, sex and race/ethnicity. Younger participants, males, and 
non-Hispanic whites had a higher cystatin C in both youth with and without diabetes 
compared to older participants, females, and black, Hispanic, and other race/ethnicity youth 
(numeric data can be found in Supplemental Table 1).
After adjusting for age, sex and race/ethnicity, the estimated mean (SE) of cystatin C was 
0.85 mg/L (0.009) in NHANES; 0.75 mg/L (0.004) in the SEARCH type 1 diabetes stratum 
and 0.70 mg/L (0.009) in the SEARCH type 2 diabetes stratum. Each pairwise comparison 
was statistically significantly different (p<0.0001).
3.2 Factors associated with cystatin C concentrations in youth with diabetes in SEARCH
Results from stepwise regression modeling are illustrated in Table 2. All three model 
selection approaches (stepwise, backwards and LASSO) arrived at the same “best” model 
for T1D. For T2D, the stepwise and backwards selection approaches included sex, race, age 
at diagnosis, duration of diabetes, HbA1c (%), and BMI Z-score while the LASSO approach 
suggested these 6 variables and fasting glucose. The p-value for fasting glucose in the model 
suggested by the LASSO method was 0.37. Furthermore, when the correlation matrix among 
these variables was calculated, we recognized that the correlation between fasting glucose 
and Hba1c (%) in T2D was 0.81 (p<0.0001) suggesting that these two variables were highly 
collinear. Therefore, the final model chosen for T2D was the model determined by the 
stepwise (and backwards) selection procedures and fasting glucose was removed. Fasting 
glucose was only significant in the group with T1D in the final model.. For every 100 mg/dL 
increase in fasting blood glucose, cystatin C decreased by 0.03 mg/L. In contrast, BMI-Z 
score was significant only in the T2D group, with a 0.04 mg/L increase in cystatin C for 
each unit increase in BMI Z-score. The HbA1c was independently associated with cystatin C 
in both T1D and T2D with a decrease in cystatin C of approximately 0.02 mg/L per unit 
increase in HbA1c.
Section 4.0 DISCUSSION
We found cystatin C concentrations to be statistically lower in youth with versus without 
diabetes; however, the magnitude of difference was quite small especially when viewed from 
the perspective of the variability of cystatin C measurements [29]. While NHANES and 
SEARCH both used a Siemens assay, the coefficient of variation for this instrument in 
different laboratories is 8%. The percent difference between the NHANES and SEARCH 
T1D sample was 12% and the difference between NHANES and SEARCH T2D sample was 
18%. A study of people with T1D versus controls with cystatin C assay performed in a 
single laboratory, found no clinical or statistical difference in the unadjusted cystatin C 
concentration, regardless of diabetes status. [21] While our results would suggest a small 
difference in cystatin C concentration between type 1 diabetes versus non-diabetic youth, 
this difference is probably not clinically meaningful when considering the bias introduced by 
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inter-laboratory variation. The difference in cystatin C concentration between the SEARCH 
T2D versus NHANES groups, however, was larger and likely does represent a true 
difference. Our study is the first to examine the distribution of cystatin C between T2D and 
non-diabetic youth and our findings warrant further investigation to both corroborate this 
result and help determine the source of this difference.
We also found a statistically significant difference in adjusted cystatin C according to 
diabetes type, with cystatin C performed in the same laboratory. The difference was small 
and may not be clinically significant. While the SEARCH assays were all performed in the 
same laboratory, the percent difference between the T1D and T2D samples was 12% and day 
to day intra-individual variability of cystatin C can be as high as 8% [30]. Further studies 
will be necessary to determine whether there is a consistent difference between diabetes 
types.
Consistent with prior studies, we found that cystatin C concentrations were slightly lower in 
females compared with males,[20, 21] and higher in non-Hispanic Whites compared with 
other races/ethnicities.[31]. There was an inverse relationship between age and cystatin C 
concentration, with lower cystatin C in 15 – 19-year-old participants compared with 12 – 14-
year-old participants, regardless of diabetes type. Our findings are discordant with 
Bokenkamp et al. [32] who reported that cystatin C did not vary by age in children without 
kidney disease. However, that study had a smaller number of patients in the 15–18 year age 
group (less than 30 vs 258 in our study). Our findings are concordant with the report of 
Groesbeck et al. [20] using NHANES data and Maahs et al. [21] which studied individuals 
with type 1 diabetes. Based on our data, holding all other variables constant, a 19-year-old 
with type 2 diabetes would have a cystatin C concentration 0.112 mg/L lower than a 12-
year-old with type 2 diabetes. Given the small effect size (beta value) for age cited by 
Groesbeck et al. (0.009), Maahs et al. (0.02), and our study (Table 2), further work is 
required to establish whether this finding is clinically significant.
Hemoglobin A1c was inversely associated with cystatin C in both T1D and T2D. Whether 
this is due to a decrease in cystatin C production versus rise in cystatin C clearance would 
need to be assessed with mechanistic and measured GFR studies. The magnitude of effect 
was also quite small, so the clinical relevance is unclear. In contrast, there was an association 
of fasting glucose with cystatin C only in T1D. The T2D group had a lower distribution of 
glucose compared to the T1D group and may have been under the threshold at which 
glucose can impact GFR, as has been previously demonstrated [33]. The impact of acute 
glycemia on cystatin C and GFR measures in patients with diabetes is generally 
underappreciated. Cherney et al. reported the ability of cystatin C to detect acute changes in 
measured GFR under hyperglycemic conditions in uncomplicated T1D [33]. Moreover, 
cystatin C based eGFR was superior to creatinine based eGFR, in detecting these changes, 
suggesting that GFR estimated by cystatin C may be preferable in diabetic persons [33] . 
Subsequently, Maahs et al. demonstrated that correction for eGFR using simultaneous 
glucose and cystatin C measures significantly improved the accuracy and precision of 
cystatin C based eGFR methods [34]. Measured GFR was not performed in the SEARCH 
study and so we cannot conclude whether the association of fasting glucose and cystatin C in 
T1D was due to differences in GFR.
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We found that BMI was a statistically significant predictor of cystatin C in participants with 
T2D but not T1D. The distribution of BMI was much higher in the T2D versus T1D sample 
which could have resulted in the difference in association. Other studies of type 1 diabetic 
cohorts have also found a lack of association between BMI and cystatin C [21]. Studies in 
nondiabetic children and adolescents have had conflicting findings regarding the association 
between BMI and cystatin C [20, 35]. In adults, one study found an increasing prevalence of 
elevated serum cystatin C (>99th percentile) with increasing BMI [36]. These authors 
postulated a role for cystatin C in adipogenesis as a possible cause for the association. 
Another study found cystatin C concentrations to be higher in obese versus non-obese adults 
and also found cystatin C mRNA in adipose cells to be twice that in non-adipose cells [37].
Our study has several limitations. Given the cross-sectional study design, we cannot make 
any causal inferences. NHANES and SEARCH are very distinct study designs, and despite 
our attempts to control for population differences, we cannot exclude the possibility of 
unmeasured differences that may have biased our comparisons. Moreover, the cystatin C 
assay was performed in different laboratories for NHANES and SEARCH and a significant 
inter-laboratory variability exists for cystatin C despite attempts at standardization. Neither 
NHANES nor SEARCH had measured GFR to decipher whether differences in cystatin C is 
due to differences in kidney function.
Strengths of our study include the large sample size and ethnic and geographic diversity of 
the SEARCH cohort, allowing for generalizability of our findings. Inclusion of both type 1 
and type 2 diabetes in the SEARCH cohort allows direct comparison between diabetes types, 
which may be important to markers of kidney function such as cystatin C. The increasing 
incidence of type 2 diabetes in youth lends great importance to the study of this population 
at high risk for future complications.
In conclusion, cystatin C concentrations appear to be slightly lower in youth with diabetes 
(especially in T2D) than nondiabetic youth and there may be differences according to 
diabetes type. Acute and chronic glycemia and BMI are characteristics which may mediate 
some of these distinctions in cystatin C. Whether these phenomenon are due to differences 
in cystatin C metabolism or are a reflection of differences in GFR are an important future 
direction of study given the recent emphasis on using cystatin C to establish eGFR 
longitudinally in individuals with diabetes and other chronic diseases.
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• Serum cystatin C levels are statistically higher in youth without diabetes 
compared to youth with type 1 or type 2 diabetes of short duration. This 
difference may not be clinically significant.
• Factors associated with serum cystatin C levels in youth with diabetes include 
age, sex, race and HbA1c.
• BMI is associated with serum cystatin C levels only in youth with type 2 
diabetes.
• Fasting glucose level is associated with serum cystatin C levels only in youth 
with type 1 diabetes.
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Figure 1. Distribution of cystatin C in SEARCH and NHANES (a) Density plot across the 
spectrum of cystatin C and (b) according to diabetes type, sex and race/ethnicity
Overall and for all subgroups: differences between NHANES and SEARCH Type 1 are 
significant (p<0.001); differences between NHANES and SEARCH Type 2 are significant 
(p<0.001);
Overall cystatin C differences between SEARCH type 1 and type 2 are significant (P<0.001) 
but differences in subgroups between SEARCH Type 1 and Type 2 are not significant at the 
<0.001 significance level
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Table 1
Demographic and clinical characteristics of participants ages 12–19 years with cystatin C (adjusted for age, 
sex and race/ethnicity) from the SEARCH for Diabetes in Youth Study, stratified by diabetes type, and 
NHANES 2001–2002 without diagnosed diabetes.









Age, years 14.9 (0.07)$& 16.3 (0.17)$# 15.5(0.12)#&
Diabetes Duration 3.6 (0.07)& 2.8 (0.2)# NA
Sex, % Male 51.3& 36.3$# 54.5&
Race/Ethnicity (%) $& $# #&
   White 76.8 19.6 62.8
   Black 9.2 45.8 13.8
   Hispanic 10.2 25.6 16.8
   Other 3.8 8.9 6.6
SBP z-score −0.5 (0.03)& 0.3 (0.08) $# −0.3 (0.07)&
DBP z-score 0.1 (0.03) $& 0.6 (0.07) $# −0.4 (0.07)#&
BMI z-score 0.7 (0.03) $& 2.1 (0.05) $# 0.5(0.06) # &
Fasting glucose, mg/dL 191.7 (2.9) 169.3 (6.8) NA
HbA1c, % 8.5 (0.06) $ 7.9 (0.2) $ 5.2 (0.01) # &
(IFCC units) (69 mmol/mol) (63 mmol/mol) (33 mmol/mol)
Albumin/Creatinine ratio (µg/mg)@ 6.6 (4.4, 12.1) 7.2 (4.3, 18.8)$ 6.3 (4.2, 11.2)&
Adjusted Cystatin C, mg/L^ 0.75 (0.004)$& 0.70 (0.01)$# 0.85 (0.01)#&
*
Restricted to age 12–19, Cystatin C measured, and Type1 or Type 2 Diabetes.
**
Restricted to age 12–19, Cystatin C measured, and non-diabetic; NHANES values reported incorporate the sampling weights for the complex 
survey design. SBP Systolic blood pressure; DBP Diastolic blood pressure;
@
median (25th, 75th percentiles) -Tests performed on log transformed values as data were not normally distributed;
$
P<0.001 compared with NHANES
#
P<0.001 compared with SEARCH Type 1
&
P<0.001 compared with SEARCH Type 2
^
Adjusted for age, sex, race/ethnicity
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Table 2








Sex (male vs female) 0.089 (0.073, 0.105) <0.0001 0.075 (0.037, 0.113) 0.0001
Race (black vs other) −0.056 (−0.084, −0.028) <0.0001 −0.036 (−0.073, 0.0002) 0.0514
Age at Diagnosis (years) −0.012 (−0.016, −0.008) <0.0001 −0.016 (−0.025, −0.007) 0.0009
Duration of DM (years) −0.012 (−0.017, −0.007) <0.0001 −0.012 (−0.023, −0.002) 0.0243
HbA1c (%) −0.015 (−0.019, −0.010) <0.0001 −0.019 (−0.025, −0.012) <0.0001
Fasting Glucose (mg/dl) −0.0003 (−0.0004, −0.0002) <0.0001 NS
BMI Z-score NS 0.038 (0.011, 0.065) 0.0058
There are 2 models above, one for each group of youth (SEARCH type 1 and type 2 diabetes). A forward selection model was used, adding the 
most significant predictor with a p-value of 0.1 or less at each iteration. Predictors with cells shaded were not included in the final model for that 
particular group of individuals.
For the categorical variables, the reference groups are female and other race. NS= not significant
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